NVCT — Nuvectis Pharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1875558 ·
Last close
$18.35
Market Cap
$578.49M
52W High
$29.27
52W Low
$8.13
ADV30
420,368
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -6,260,000 | -6,050,000 | 25,398,000 | 25,130,000 | 11,178,000 |
| Dec 2025 | 0 | — | -7,617,000 | -7,314,000 | 31,709,000 | 31,634,000 | 13,296,000 |
| Sep 2025 | 0 | — | -7,794,000 | -7,462,000 | 35,587,000 | 35,442,000 | 11,577,000 |
| Jun 2025 | 0 | — | -6,595,000 | -6,334,000 | 27,007,000 | 26,793,000 | 10,135,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-16,009,000
Investing CF
$0
Financing CF
$29,110,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.25
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-99,687,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-27,574,000
Pretax Income TTM
$-26,442,000
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -27,574,000 | -26,442,000 | 31,709,000 | 13,296,000 | — | -16,009,000 |
| Dec 2024 | 0 | -19,847,000 | -19,000,000 | 18,607,000 | 8,894,000 | — | -12,247,000 |
| Dec 2023 | 0 | -22,897,000 | -22,260,000 | 19,185,000 | 6,984,000 | — | -15,954,000 |
| Dec 2022 | 0 | -19,234,000 | -19,085,000 | 20,405,000 | 6,186,000 | — | -13,559,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.96
Max Pain — expiry 2026-10-16
max pain strike: $10.00 · spot: $18.35 · call oi: 8,539 · put oi: 223
Expected Move to 2026-10-16:
±$11.28
(61.44%) —
implied range
$7.08 –
$29.63
· ATM straddle on $17.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ANL | Adlai Nortye Ltd. | $579.71M | $9.87 | — |
| ALT | Altimmune, Inc. | $593.15M | $3.05 | — |
| ASMB | ASSEMBLY BIOSCIENCES, INC. | $542.99M | $27.40 | — |
| ARVN | ARVINAS, INC. | $533.59M | $8.27 | — |
| STTK | Shattuck Labs, Inc. | $634.17M | $6.64 | — |
News headlines (Yahoo Finance, 1h cache)
Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
2026-07-08 13:55 · Yahoo
What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now?
2026-07-01 16:00 · Yahoo
Nuvectis Pharma shares slide after pricing $100 million discounted stock offering (NVCT)
2026-06-30 12:36 · Yahoo
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
2026-06-30 02:30 · Yahoo
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
2026-06-29 20:01 · Yahoo
What Makes Nuvectis Pharma (NVCT) a New Buy Stock
2026-06-26 16:00 · Yahoo
Haisco and Nuvectis sign licensing deal for two drugs
2026-06-24 09:10 · Yahoo
Haisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology and Complement Indications
2026-06-23 13:17 · Yahoo
Nuvectis Expands Pipeline with Haisco Licensing Agreement for Two Clinical-Stage Drug Candidates (NVCT)
2026-06-22 12:53 · Yahoo
Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
2026-06-22 11:30 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-07-01 13:39:50 | 2026-06-30 | Bentsur Ron | COB, CEO, 10% | P - Purchase | 20 | 12500 | 250000 |
| 2026-07-01 13:41:50 | 2026-06-30 | Mosseri Marlio Charles | 10% | P - Purchase | 18.32 | 50000 | 916000 |